Trial reportThe Journal of urology2018
Prostate Specific Membrane Antigen Targeted
Trial report in The Journal of urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05936658 (A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer), which is not on this map. Cited by 48 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer
Who cites it
48 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2020Pooled it
- Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- AnCurrent radiopharmaceuticals · 2024Trial
- [European journal of nuclear medicine and molecular imaging · 2023Trial
- Trial
- Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT withThe Journal of urology · 2021Trial
- Diagnostic Performance ofClinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Pelvic lymph-node staging withEuropean journal of nuclear medicine and molecular imaging · 2021Trial
- [The Journal of urology · 2020Trial
- Prospective Evaluation of PSMA-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Trial
- A Prospective Study onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Trial
- Diagnostic and therapeutic impact of PET/CT with 18F-DCFPyL versus 18F-Fluorocholine in initial staging of intermediate-/high-risk prostate cancer: a pilot study.Annals of nuclear medicine · 2023Article
- Clinical advancement of precision theranostics in prostate cancer.Frontiers in oncology · 2023Review
- Predictors ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Molecular imaging in oncology: Current impact and future directions.CA: a cancer journal for clinicians · 2022Review
- Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends.Journal of clinical medicine · 2022Review
- Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Evaluation of a radiomics nomogram derived from Fluoride-18 PSMA-1007 PET/CT for risk stratification in newly diagnosed prostate cancer.Frontiers in oncology · 2022Article
- New imaging modalities to consider for men with prostate cancer on active surveillance.World journal of urology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
purposeWe prospectively evaluated the diagnostic performance of prostate specific membrane antigen targeted MATERIALS AND
methodsMen with clinically localized high or very high risk prostate cancer were imaged with
resultsA total of 25 men contributed analyzable data to this study. Seven of these patients (28%) were found to have 1 or more positive lymph nodes on surgical pathology. Sites of radiotracer uptake were identified in the prostate of all imaged patients. The 2 readers identified the same number of prostatic lesions in 22 patients (88%), of whom all had at least 1 intraprostatic lesion in common between the 2 reads. Additionally, the readers assigned the same N stage to 46 of 50 individual lymph node packets (92%). Following reconciliation of the relatively few discordant imaging reads, 7 patients (28%) were found to have 1 or more sites of radiotracer uptake in the pelvis consistent with N1 disease, resulting in 71.4% sensitivity (95% CI 29.0-96.3) and 88.9% specificity (95% CI 65.3-98.6). Analysis at the level of individual nodal packets resulted in 66.7% sensitivity (95% CI 29.9-92.5) and 92.7% specificity (95% CI 80.1-98.5). Three men (12%) had evidence of M1a disease.
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.